Anti-AQP4 autoantibodies promote ATP release from astrocytes and induce mechanical pain in rats.
ATP
IL-1β
NMOSD
Pain
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
21 Aug 2021
21 Aug 2021
Historique:
received:
19
02
2021
accepted:
04
08
2021
entrez:
22
8
2021
pubmed:
23
8
2021
medline:
27
1
2022
Statut:
epublish
Résumé
Intractable neuropathic pain is a common symptom of neuromyelitis optica spectrum disorder (NMOSD). However, the underlying mechanism of NMOSD pain remains to be elucidated. In this study, we focused on ATP, which is one of the damage-associated molecular patterns, and also a well-recognized molecule involved in peripheral neuropathic pain. We assessed the development of pain symptoms by injecting anti-AQP4 recombinant autoantibodies (rAQP4 IgG) into rat spinal cords. We incubated HEK293 cells expressing AQP4 (HEK-AQP4) and rat astrocytes with rAQP4 IgG and assessed the level of ATP in the supernatant. We performed transcriptome analysis of the spinal cords injected with rAQP4 IgG. Pharmacological inhibition was also applied to investigate the involvement of ATP in the development of neuropathic pain in our rat model. The ATP concentration within the cerebrospinal fluid was examined in patients with NMOSD and other neurological diseases. Development of mechanical allodynia was confirmed in rAQP4 IgG-treated rats. AQP4-Ab-mediated extracellular ATP release from astrocytes was observed in vitro, and pharmacological inhibition of ATP receptor reversed mechanical allodynia in the rAQP4 IgG-treated rats. Furthermore, transcriptome analysis revealed elevation of gene expressions related to several ATP receptors including P2rx4 and IL1B in the spinal cord of rAQP4 IgG-treated rats. In patients, CSF ATP concentration was significantly higher in the acute and remission phase of NMOSD than in multiple sclerosis or other neurological disorders. Anti-AQP4 antibody was shown to induce the release of extracellular ATP from astrocytes. The ATP-mediated development of mechanical allodynia was also suggested in rats treated with anti-AQP4 antibody. Our study indicates the pivotal role of ATP in the pain mechanism of NMOSD.
Sections du résumé
BACKGROUND
BACKGROUND
Intractable neuropathic pain is a common symptom of neuromyelitis optica spectrum disorder (NMOSD). However, the underlying mechanism of NMOSD pain remains to be elucidated. In this study, we focused on ATP, which is one of the damage-associated molecular patterns, and also a well-recognized molecule involved in peripheral neuropathic pain.
METHODS
METHODS
We assessed the development of pain symptoms by injecting anti-AQP4 recombinant autoantibodies (rAQP4 IgG) into rat spinal cords. We incubated HEK293 cells expressing AQP4 (HEK-AQP4) and rat astrocytes with rAQP4 IgG and assessed the level of ATP in the supernatant. We performed transcriptome analysis of the spinal cords injected with rAQP4 IgG. Pharmacological inhibition was also applied to investigate the involvement of ATP in the development of neuropathic pain in our rat model. The ATP concentration within the cerebrospinal fluid was examined in patients with NMOSD and other neurological diseases.
RESULTS
RESULTS
Development of mechanical allodynia was confirmed in rAQP4 IgG-treated rats. AQP4-Ab-mediated extracellular ATP release from astrocytes was observed in vitro, and pharmacological inhibition of ATP receptor reversed mechanical allodynia in the rAQP4 IgG-treated rats. Furthermore, transcriptome analysis revealed elevation of gene expressions related to several ATP receptors including P2rx4 and IL1B in the spinal cord of rAQP4 IgG-treated rats. In patients, CSF ATP concentration was significantly higher in the acute and remission phase of NMOSD than in multiple sclerosis or other neurological disorders.
CONCLUSION
CONCLUSIONS
Anti-AQP4 antibody was shown to induce the release of extracellular ATP from astrocytes. The ATP-mediated development of mechanical allodynia was also suggested in rats treated with anti-AQP4 antibody. Our study indicates the pivotal role of ATP in the pain mechanism of NMOSD.
Identifiants
pubmed: 34419102
doi: 10.1186/s12974-021-02232-w
pii: 10.1186/s12974-021-02232-w
pmc: PMC8380350
doi:
Substances chimiques
Aquaporin 4
0
Autoantibodies
0
Adenosine Triphosphate
8L70Q75FXE
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
181Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP18H05282
Organisme : Japan Society for the Promotion of Science
ID : JP18K15451
Informations de copyright
© 2021. The Author(s).
Références
Exp Neurol. 2012 Apr;234(2):362-72
pubmed: 22036747
Ann Neurol. 2009 Nov;66(5):617-29
pubmed: 19938104
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Cell Rep. 2012 Apr 19;1(4):334-340
pubmed: 22832225
J Neurol Neurosurg Psychiatry. 2013 May;84(5):517-22
pubmed: 23255728
Lancet Neurol. 2007 Sep;6(9):805-15
pubmed: 17706564
Sci Rep. 2020 Aug 6;10(1):13274
pubmed: 32764561
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Neuroreport. 2009 Mar 25;20(5):508-12
pubmed: 19297740
J Biol Chem. 2009 May 15;284(20):13446-13454
pubmed: 19304656
Acta Neuropathol Commun. 2013 May 08;1:5
pubmed: 24252536
Nat Neurosci. 2015 Aug;18(8):1081-3
pubmed: 26120961
Nat Rev Immunol. 2020 Feb;20(2):95-112
pubmed: 31558839
Neuron. 2018 Dec 19;100(6):1292-1311
pubmed: 30571942
Nature. 2003 Aug 14;424(6950):778-83
pubmed: 12917686
Biochem Biophys Res Commun. 2013 Mar 15;432(3):406-11
pubmed: 23428419
Glia. 2014 Jul;62(7):1093-109
pubmed: 24677092
Biochem Biophys Res Commun. 2015 Nov 20;467(3):484-90
pubmed: 26456657
Biochem Biophys Res Commun. 2009 Sep 4;386(4):623-7
pubmed: 19545538
Pain. 2000 Aug;87(2):149-158
pubmed: 10924808
Neurosci Lett. 2011 Oct 17;504(1):57-61
pubmed: 21924325
Acta Neuropathol. 2019 Mar;137(3):467-485
pubmed: 30564980
iScience. 2018 Aug 31;6:306-318
pubmed: 30240621
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Glia. 2019 Mar;67(3):482-497
pubmed: 30578561
Front Cell Neurosci. 2013 Oct 28;7:191
pubmed: 24191146
BMC Bioinformatics. 2018 Dec 19;19(1):534
pubmed: 30567491
Neuroscience. 2007 Jun 29;147(2):445-55
pubmed: 17543465
Nat Rev Neurol. 2014 Sep;10(9):529-36
pubmed: 25072195
Nat Commun. 2014 May 13;5:3771
pubmed: 24818655
Pain. 2013 Dec;154 Suppl 1:S10-S28
pubmed: 23792284
Lancet Neurol. 2019 Feb;18(2):185-197
pubmed: 30663608
Brain. 2021 Mar 12;:
pubmed: 33711152
Arch Neurol. 2012 Nov;69(11):1482-7
pubmed: 22926050
Nat Commun. 2016 Aug 12;7:12529
pubmed: 27515581
J Neurosci Res. 2001 Nov 1;66(3):487-96
pubmed: 11746367
J Neurol. 2013 Aug;260(8):2134-7
pubmed: 23689970
J Neuroinflammation. 2018 Apr 27;15(1):125
pubmed: 29703264
Ann Neurol. 2009 Nov;66(5):630-43
pubmed: 19937948